文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

成人重症监护液体过载患者的袢利尿剂:随机临床试验的系统评价及荟萃分析和试验序贯分析

Loop diuretics in adult intensive care patients with fluid overload: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
PubMed 文献 · Ann Intensive Care · 2022-06-13
一句话结论在成人ICU液体过载患者中,袢利尿剂对死亡率及严重不良事件影响的证据极不确定;与安慰剂/无干预相比全因死亡无差异(RR 0.72,95%CI 0.49-1.06),严重不良事件较少(RR 0.81,95%CI 0.66-0.99),但试验序贯分析对此存疑。

该系统评价纳入10项随机临床试验(804例成人ICU液体过载患者),比较单一袢利尿剂与其他干预,所有试验总体偏倚风险高。与安慰剂/无干预相比,全因死亡无差异(RR 0.72,95%CI 0.49-1.06;4项试验;359例;I²=0%;TSA校正CI 0.15-3.48;证据确定性极低);袢利尿剂组严重不良事件较少(RR 0.81,95%CI 0.66-0.99;6项试验;476例;I²=0%;证据确定性极低),但试验序贯分析对此存疑(TSA校正CI 0.55-1.20)。作者结论为证据极不确定,袢利尿剂可能减少上述结局发生,但需要低偏倚风险的大型随机安慰剂对照试验。

要点

  • 成人ICU液体过载患者中,袢利尿剂与安慰剂/无干预相比全因死亡无差异:RR 0.72(95%CI 0.49-1.06;4项试验;359例;I²=0%;TSA校正CI 0.15-3.48;证据确定性极低)。
  • 袢利尿剂组严重不良事件较少:RR 0.81(95%CI 0.66-0.99;6项试验;476例;I²=0%;证据确定性极低),但试验序贯分析对此存疑(TSA校正CI 0.55-1.20)。
  • 该系统评价纳入10项随机临床试验共804例成人ICU液体过载患者,所有试验总体偏倚风险高。
  • 作者结论:袢利尿剂对死亡率和严重不良事件影响的证据极不确定,袢利尿剂可能减少这些结局的发生,但需要低偏倚风险的大型随机安慰剂对照试验。

适用人群与场景

  • 成人重症监护病房(ICU)液体过载患者。

研究设计与关键结果

  • 研究设计:系统评价及荟萃分析和试验序贯分析(TSA),比较单一袢利尿剂与其他干预,纳入随机临床试验,遵循已发表方案、Cochrane手册和PRISMA声明,采用ROB2工具评估偏倚风险、GRADE评估证据确定性,注册于PROSPERO(CRD42020184799)。
  • 纳入10项试验共804例参与者,所有试验总体偏倚风险高。
  • 袢利尿剂 vs 安慰剂/无干预:全因死亡无差异(RR 0.72,95%CI 0.49-1.06;4项试验;359例参与者;I²=0%;TSA校正CI 0.15-3.48;证据确定性极低)。
  • 袢利尿剂 vs 安慰剂/无干预:袢利尿剂组严重不良事件较少(RR 0.81,95%CI 0.66-0.99;6项试验;476例参与者;I²=0%;证据确定性极低),但试验序贯分析对此存疑(TSA校正CI 0.55-1.20)。

证据类型、等级与局限

  • 证据类型:随机临床试验的系统评价及荟萃分析和试验序贯分析。
  • 证据确定性:GRADE评估为极低(全因死亡和严重不良事件结局)。
  • 局限:所有纳入试验总体偏倚风险高;证据确定性极低;试验序贯分析对严重不良事件结果存疑;作者指出需要低偏倚风险的大型随机安慰剂对照试验。

对床旁实践的改变

  • 作者结论认为,袢利尿剂对成人ICU液体过载患者死亡率和严重不良事件影响的证据极不确定;袢利尿剂可能减少这些结局的发生,但需要低偏倚风险的大型随机安慰剂对照试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Fluid overload is a risk factor for organ dysfunction and death in intensive care unit (ICU) patients, but no guidelines exist for its management. We systematically reviewed benefits and harms of a single loop diuretic, the predominant treatment used for fluid overload in these patients.

METHODS: We conducted a systematic review with meta-analysis and Trial Sequential Analysis (TSA) of a single loop diuretic vs. other interventions reported in randomised clinical trials, adhering to our published protocol, the Cochrane Handbook, and PRISMA statement. We assessed the risks of bias with the ROB2-tool and certainty of evidence with GRADE. This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42020184799).

RESULTS: We included 10 trials (804 participants), all at overall high risk of bias. For loop diuretics vs. placebo/no intervention, we found no difference in all-cause mortality (relative risk (RR) 0.72, 95% confidence interval (CI) 0.49-1.06; 4 trials; 359 participants; I2 = 0%; TSA-adjusted CI 0.15-3.48; very low certainty of evidence). Fewer serious adverse events were registered in the group treated with loop diuretics (RR 0.81, 95% CI 0.66-0.99; 6 trials; 476 participants; I2 = 0%; very low certainty of evidence), though contested by TSA (TSA-adjusted CI 0.55-1.20).

CONCLUSIONS: The evidence is very uncertain about the effect of loop diuretics on mortality and serious adverse events in adult ICU patients with fluid overload. Loop diuretics may reduce the occurrence of these outcomes, but large randomised placebo-controlled trials at low risk of bias are needed.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Wichmann S, Barbateskovic M, Liang N, et al. Loop diuretics in adult intensive care patients with fluid overload: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Ann Intensive Care. 2022. PMID: 35696008. doi:10.1186/s13613-022-01024-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。